Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Volavka

Showing results (121-130 of 146) with videos related to

Pageof 15
Sort By:
The International Journal of Neuroscience|June 1, 1986
Brain responses to sine wave modulated light (SML): reliability and relationship to spontaneous EEGV E Pollock, J Volavka, W F Gabrielli, et al.
Biological Psychiatry|August 1, 1979
Antiparkinsonics, neuroleptics, and tardive dyskinesiaA Mallya, C Jose, M Baig, et al.
The Annals of Pharmacotherapy|October 1, 1993
Pharmacoepidemiology of clozapine in 202 inpatients with schizophreniaJ M Zito, J Volavka, T J Craig, et al.
Biological Psychiatry|October 15, 1990
Tryptophan treatment of aggressive psychiatric inpatientsJ Volavka, M Crowner, D Brizer, et al.
Psychophysiology|July 1, 1982
Electroencephalograms in children of alcoholic fathersW F Gabrielli, S A Mednick, J Volavka, et al.
Advances in Experimental Medicine and Biology|January 1, 1979
Hormonal and other effects of naltrexone in normal menJ Volavka, A Mallya, J Bauman, et al.
Psychiatry Research|December 1, 1982
Naloxone, tardive dyskinesia, and endogenous beta-endorphinD Reker, B Anderson, C Yackulic, et al.
Acta Psychiatrica Scandinavica|September 1, 1988
Pattern reversal visual evoked potential among men at risk for alcoholismV E Pollock, J Volavka, W F Gabrielli, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|December 15, 2015
Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studiesJ Volavka, R A Van Dorn, L Citrome, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 1, 1994
BMY 14802, a sigma receptor ligand for the treatment of schizophreniaG R Gewirtz, J M Gorman, J Volavka, et al.
Pageof 15

Showing results (121-130 of 146) with videos related to

Sort By:
Pageof 15
The International Journal of Neuroscience|June 1, 1986
Brain responses to sine wave modulated light (SML): reliability and relationship to spontaneous EEGV E Pollock, J Volavka, W F Gabrielli, et al.
Biological Psychiatry|August 1, 1979
Antiparkinsonics, neuroleptics, and tardive dyskinesiaA Mallya, C Jose, M Baig, et al.
The Annals of Pharmacotherapy|October 1, 1993
Pharmacoepidemiology of clozapine in 202 inpatients with schizophreniaJ M Zito, J Volavka, T J Craig, et al.
Biological Psychiatry|October 15, 1990
Tryptophan treatment of aggressive psychiatric inpatientsJ Volavka, M Crowner, D Brizer, et al.
Psychophysiology|July 1, 1982
Electroencephalograms in children of alcoholic fathersW F Gabrielli, S A Mednick, J Volavka, et al.
Advances in Experimental Medicine and Biology|January 1, 1979
Hormonal and other effects of naltrexone in normal menJ Volavka, A Mallya, J Bauman, et al.
Psychiatry Research|December 1, 1982
Naloxone, tardive dyskinesia, and endogenous beta-endorphinD Reker, B Anderson, C Yackulic, et al.
Acta Psychiatrica Scandinavica|September 1, 1988
Pattern reversal visual evoked potential among men at risk for alcoholismV E Pollock, J Volavka, W F Gabrielli, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|December 15, 2015
Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studiesJ Volavka, R A Van Dorn, L Citrome, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 1, 1994
BMY 14802, a sigma receptor ligand for the treatment of schizophreniaG R Gewirtz, J M Gorman, J Volavka, et al.
Pageof 15